Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis

P M Parikh; S R Shah; S C Shah; V Sheth; R A Patel; K C Shah; P K Jain

Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis

Indian J Cancer. 1996 Mar;33(1):17-20.

Authors

P M Parikh¹, S R Shah, S C Shah, V Sheth, R A Patel, K C Shah, P K Jain

Affiliation

¹ Sir Hurkisondas Narrotumdas Hospital, Padmashree Gordhanbapa Chowk, Mumbai, India.

PMID: 9063013

Abstract

Ondansetron was used as an antiemetic along with dexamethasone during 16 cycles of highly or moderately ematogenic chemotherapy. There was major control in two cycles and complete control in the remaining 14. Side effects were minor and did not require discontinuation of the drug. This combination, therefore, appears to be safe and effective in preventing chemotherapy induced emesis.

Publication types

Clinical Trial

MeSH terms

Adult
Antiemetics / adverse effects
Antiemetics / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Dexamethasone / adverse effects
Dexamethasone / therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Ondansetron / adverse effects
Ondansetron / therapeutic use*
Receptors, Serotonin / drug effects*
Receptors, Serotonin / physiology
Receptors, Serotonin, 5-HT3
Serotonin Antagonists / adverse effects
Serotonin Antagonists / therapeutic use*
Vomiting / prevention & control*

Substances

Antiemetics
Receptors, Serotonin
Receptors, Serotonin, 5-HT3
Serotonin Antagonists
Ondansetron
Dexamethasone